Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (DE:GIS)
XETRA:GIS
Gilead Sciences (GIS) Stock Price & Analysis
5 Followers
GIS Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€61.77 - €79.18
Previous Close€62.94
Volume19.00
Average Volume (3M)970.00
Market Cap
€78.04B
Enterprise Value€100.22B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$24.98B
Price to Earnings (P/E)15.1
Beta0.32
Next Earnings
Aug 08, 2024EPS Estimate
€1.58Last Dividend Ex-Date
Mar 14, 2024Dividend Yield4.5%
Share Statistics
EPS (TTM)4.16
Shares Outstanding1,245,774,616
10 Day Avg. Volume637
30 Day Avg. Volume970
Standard Deviation0.07
R-Squared0.00175
Alpha0.00828
Financial Highlights & Ratios
Price to Book (P/B)-7.00
Price to Sales (P/S)2.85
Price to Cash Flow (P/CF)9.60
P/FCF Ratio9.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.63
Enterprise Value/Ebitda9.38
Forecast
1Y Price Target
€79.06Price Target Upside25.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
Growth OpportunitiesAnalyst expects focus to be on progress and expectations for growth drivers, indicating potential future revenue and profit for the company.
Product LaunchThe potential launch of seladelpar in primary biliary cholangitis (PBC) presents a new opportunity for revenue growth in Gilead's liver business.
Strategic ExpansionU.S. expansion into the community setting is a strategic move that could streamline processes and enhance accessibility.
Bears Say
Financial PerformanceAnalyst's revenue estimate for Gilead has been decreased, aligning with a consensus that reflects no expected outperformance.
Oncology Segment PerformanceThere is uncertainty in GILD's oncology segment, with first quarter sales of Trodelvy and CellTx potentially underperforming against market expectations.
Product SalesGILD's first quarter HIV sales are expected to fall short of expectations, driven by a decrease in sales of key products like Biktarvy, Descovy, and Genvoya.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.90% Insiders
30.60% Mutual Funds
27.95% Other Institutional Investors
40.55% Public Companies and
Individual Investors
GIS FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was €61.77 and its highest was €79.18 in the past 12 months.
What is Gilead Sciences’s market cap?
Currently, no data Available
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Aug 08, 2024 which is in 102 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Apr 25, 2024. The company reported -€1.233 earnings per share for the quarter, beating the consensus estimate of -€1.394 by €0.162.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of €0.72 which represents an annual dividend yield of 4.5%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is €1.58.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,246,969,400 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of -€1.233 in its last earnings report, beating expectations of -€1.394. Following the earnings report the stock price went down -3.735%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 3B.
---
Gilead Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€79.06 (25.31% Upside)
€79.06 (25.31% Upside)
Blogger Sentiment
Bullish
DE:GIS Sentiment 93%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.58%
12-Months-Change
Fundamentals
Return on Equity
25.71%
Trailing 12-Months
Asset Growth
-1.66%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
GIS Company Deck
---
GIS Earnings Call
Q4 2024
0:00 / 0:00
---
GIS Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
GIS Stock 12 Months Forecast
Average Price Target
€79.06
▲(25.31% Upside)
Technical Analysis
Best Analysts Covering GIS
1 Year
1 Year Success Rate
31/57 ratings generated profit
1 Year Average Return
+5.73%
reiterated a buy rating last month
Copying Salim Syed's trades and holding each position for 1 Year would result in 54.39% of your transactions generating a profit, with an average return of +5.73% per trade.
---